novel therapeutics in essential thrombocythemia
Published 1 year ago • 404 plays • Length 0:35Download video MP4
Download video MP3
Similar videos
-
1:25
exciting updates in essential thrombocythemia: exploring novel agents
-
1:26
agents of interest being explored in essential thrombocythemia and polycythemia vera
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
1:57
surpass et: p1101 in essential thrombocythemia
-
0:57
novel therapeutic strategies in all
-
1:43
updates from a phase ii study of bomedemstat for the treatment of essential thrombocythemia
-
1:06:04
itp: novel treatments
-
3:53
essential thrombocythemia watch & wait | what patients should know
-
3:33
transformation of essential thrombocythemia
-
0:45
non-pharmaceutical interventions for patients with mpns and other hematological malignancies
-
2:05
the surpass-et study: evaluating novel treatment approaches in et
-
2:15
advances in the risk stratification and treatment of essential thrombocythemia
-
0:46
factors associated with progression to myelofibrosis in patients with essential thrombocythemia
-
2:24
update on phase iib study of bomedemstat in essential thrombocythemia
-
5:21
challenges in the treatment and management of et and the need to improve therapeutic approaches
-
1:36
are novel therapeutics replacing asct?
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:11
exciting updates in all and the value of novel immunotherapies
-
8:07
essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies
-
6:38
novel approaches for mpns
-
1:34
are thrombotic risk and progression in et predictable?